Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia) - INAHTA Brief
To assess the clinical utility (impact on healthcare), the diagnostic accuracy and safety of endomicroscopy-based biopsy method in comparison to the standard of care during an endoscopic evaluation of patients with Barrett’s esophagus (BE) using white light endoscopy (WLE) +/- high-definition (HD) view. The standard of care is currently the Seattle protocol which correspond to biopsy any visible lesion and practice complementary random four-quadrant biopsy of the remaining metaplastic mucosa. The aim of this heath technology assessment (HTA) is to decide on the coverage by French National Health Insurance of medical procedure using esophagus’s endomicroscopy in two different clinical situations: surveillance of patients with non-dysplastic BE (for diagnosis of BE early neoplasia) or pre-therapeutic mapping with dysplastic BE (for diagnosis of synchronous early neoplasia). The target lesion in this assessment was early oesophageal adenocarcinoma[1].
[1] It includes high-grade dysplasia (HGD) and intramucosal carcinoma (IMC).